ReviewTargeted oncology2010
Targeted therapies for renal cell carcinoma: understanding their impact on survival.
Review in Targeted oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Pooled it
- Targeted therapy for advanced renal cell carcinoma.The Cochrane database of systematic reviews · 2008Pooled it
- Renal cell cancer with solitary gastric metastasis: a rare presentation.BMJ case reports · 2021Article
- LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma.Cancer biomarkers : section A of Disease markers · 2017Article
- Metastasis in renal cell carcinoma: Biology and implications for therapy.Asian journal of urology · 2016Review
- Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?BioMed research international · 2015Review
- NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.Molecular cancer therapeutics · 2013Article
- Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.Journal of geriatric oncology · 2013Article
- Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2013Review
- Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.PloS one · 2013Article
- Update on targeted therapies for clear cell renal cell carcinoma.Current opinion in oncology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Within the past 5 years, the United States Food and Drug Administration have approved six targeted agents for the treatment of metastatic renal cell carcinoma (mRCC). While this offers great potential to patients afflicted with this disease, oncologists are faced with the challenge of applying each agent in the appropriate clinical setting. Doing so requires an intricate understanding of the pivotal trials evaluating these agents. Herein, we have provided a detailed analysis of the study design employed in these trials. Use of appropriate comparator arms for targeted therapies (i.e., interferon-alpha or placebo) is addressed. Furthermore, we discuss the relative merits of using progression-free survival (PFS) or overall survival (OS) as a primary endpoint-importantly, the two endpoints may not be precisely correlated. Strategies to appropriately interpret OS in the context of post-study therapies and crossover designs are described. Ultimately, head-to-head trials comparing targeted therapies are necessary to resolve clinical equipoise. Several ongoing efforts juxtaposing the approved agents for mRCC are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.